PMV Pharmaceuticals, Inc.
PMVP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001699382
No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q2 2026, worth $45.9M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in PMV Pharmaceuticals, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- −2 vs. Q2 2023
- Shares held
- 54.2M
- +2.48M (+4.8%) vs. Q2 2023
- Total value
- $333.0M
- +$9.02M (+2.8%) vs. Q2 2023
- New holders
- 8
- 41 more added
- Sold out
- 10
- 33 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PMVP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 64 | $45.9M |
| Q1 2026 | 69 | $45.8M |
| Q4 2025 | 63 | $46.8M |
| Q3 2025 | 64 | $52.5M |
| Q2 2025 | 54 | $36.8M |
| Q1 2025 | 55 | $40.7M |
| Q4 2024 | 70 | $58.8M |
| Q3 2024 | 74 | $58.2M |
| Q2 2024 | 93 | $65.6M |
| Q1 2024 | 99 | $72.7M |
| Q4 2023 | 98 | $144.0M |
| Q3 2023 | 104 | $333.0M |
| Q2 2023 | 106 | $324.0M |
| Q1 2023 | 113 | $245.7M |
| Q4 2022 | 115 | $474.5M |
| Q3 2022 | 120 | $692.3M |
| Q2 2022 | 105 | $870.9M |
| Q1 2022 | 99 | $1.15B |
| Q4 2021 | 105 | $1.10B |
| Q3 2021 | 92 | $1.31B |
| Q2 2021 | 86 | $1.44B |
| Q1 2021 | 81 | $1.31B |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding PMV Pharmaceuticals, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Boxer Capital, LLC | 3,163,795 | $19.4M | 1.03% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 4,033,721 | $24.8M | 0.00% | −41,783−1.0% | Reduced |
| BlackRock Inc. | 4,596,378 | $28.2M | 0.00% | −80,650−1.7% | Reduced |
| OrbiMed Advisors LLC | 6,563,077 | $40.3M | 0.93% | 00.0% | Unchanged |
| Bank of Montreal | 0 | $0 | 0.00% | −698,184−100.0% | Sold out |
| Sphera Funds Management Ltd. | 0 | $0 | 0.00% | −187,800−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −48,323−100.0% | Sold out |
| UBS Asset Management Americas Inc | 0 | $0 | 0.00% | −62,355−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −41,800−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −33,360−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −27,225−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −19,041−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −11,471−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −1,592−100.0% | Sold out |